Quarterly report pursuant to Section 13 or 15(d)

Collaboration Arrangements - Additional Information (Detail)

v3.2.0.727
Collaboration Arrangements - Additional Information (Detail) - Merck KGaA - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront and milestone payments received to date     $ 110.0  
Merck KGaA's percentage share of worldwide development expenses     70.00%  
Revenue recognized by the Company $ 3.7 $ 3.7 $ 7.4 $ 7.4
Company received a reimbursement for eligible worldwide development expenses $ 3.6 $ 3.5 $ 5.6 $ 9.4
United States        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Portion of profits that Company is eligible to participate, depending upon total sales     50.00%  
Regulatory and Development Milestones | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Potential future milestones     $ 100.0  
Commercialization Milestones | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Potential future milestones     $ 340.0